

07-13-00

07/12/00

jc862 U.S. PTO

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> (Only for new non-provisional applications under 37CFR§1.53(b))		Attorney Docket No.	HME/7982.001
		First Inventor or Application Identifier	Sharon F. Kleyne
		Title	METHOD AND KIT FOR MOISTURIZING THE SURFACE OF THE EYE
		Express Mail Label No.	EL619333956US

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231
--	--

1. <input checked="" type="checkbox"/> *Fee Transmittal Form (e.g. PTO/SB/17) (Submit an original and a duplicate for fee processing)	5. <input type="checkbox"/> Microfiche Computer Program (Appendix)
2. <input checked="" type="checkbox"/> Specification <span style="float: right;">Total pages <b>14</b></span> (preferred arrangement set forth below) <ul style="list-style-type: none"> <li>- Descriptive Title of the Invention</li> <li>- Cross References to Related Applications</li> <li>- Statement Regarding Federally Sponsored Research</li> <li>- Reference to Microfiche Appendix</li> <li>- Background of the Invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings (if filed)</li> <li>- Detailed Description</li> <li>- Claim(s)</li> <li>- Abstract of the Disclosure</li> </ul>	6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) <ul style="list-style-type: none"> <li>a. <input type="checkbox"/> Computer readable copy</li> <li>b. <input type="checkbox"/> Paper copy (identical to computer copy)</li> <li>c. <input type="checkbox"/> Statement verifying identity of above copies</li> </ul>
3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) <span style="float: right;">[Total Pages <b>1</b>]</span>	<b>ACCOMPANYING APPLICATION PARTS</b>
4. Oath or Declaration <span style="float: right;">[Total Pages <b>2</b>]</span> <ul style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> Newly executed (original or copy)</li> <li>b. <input type="checkbox"/> Copy from a prior application (37 CFR §1.63(d))          (for continuation/divisional with Box 16 completed)           <ul style="list-style-type: none"> <li>i. <input type="checkbox"/> Deletion of Inventor(s)            Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§1.53(d)(2) and 1.33(b)</li> </ul> </li> </ul>	
16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No.: _____ Prior application information: Examiner _____ Group No./Art Unit _____ <b>For CONTINUATION or DIVISIONAL APPS only:</b> The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.	
17. CORRESPONDENCE ADDRESS	
<input type="checkbox"/> Customer Number or Bar Code Label <span style="float: right;">(Insert customer number or attach bar code label here)</span> or <input checked="" type="checkbox"/> Correspondence address below	
Name <b>Chernoff, Vilnauer, McClung &amp; Stenzel, LLP</b>	
Address <b>601 S.W. Second Avenue, Suite 1600</b>	
City <b>Portland</b>	State <b>Oregon</b> Zip Code <b>97204</b>
Country <b>U.S.A.</b>	Telephone <b>(503) 227-5631</b> FAX <b>(503) 228-4373</b>
Name (print type) <b>Howard M. Eisenberg</b>	Registration No. (Attorney/Agent) <b>36,789</b>
Signature <i>Howard Eisenberg</i>	Date <b>July 12, 2000</b>

\* Note for Items 1 & 13: In order to be entitled to pay small entity fees, a small entity statement is required (37 CFR §1.27), except if one filed in a prior application is relied upon (37 CFR §1.28)

jc490 U.S. PTO  
06/19/00  
07/12/00

07/12/00

CERTIFICATE OF MAILING

BY "EXPRESS MAIL"

Express Mail No.: EL619333956US

Date of Deposit : July 12, 2000

I hereby certify that the utility patent application attached hereto entitled METHOD AND KIT FOR MOISTURIZING THE SURFACE OF THE EYE, Sharon F. Kleyne, inventor(s), together with Fee Transmittal form (duplicate), Utility Patent Application Transmittal form (duplicate), Declaration, Power of Attorney, Small Entity Statement, Assignment and cover sheet, and the required fees, is being deposited with the United States Postal Service "Express Mail to Addressee" on the date indicated above and is addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.


  
Dwight Berquist-Moody

## PATENT APPLICATION EXAMINING OPERATIONS

**STATEMENT OF STATUS AS SMALL ENTITY  
IN ACCORDANCE WITH 37 CFR §1.27**

AND that the Company is under no obligation under contract or law to assign, grant, convey, or license any rights in the invention except to: NONE

**DATED:**

  
**Willem Kleyne**  
**Chief Executive Officer**  
**Rogue Valley Natural**  
**Springs, Inc.**

## METHOD AND KIT FOR MOISTURIZING THE SURFACE OF THE EYE

The invention pertains to the field of care and therapy of the surface of the eye, including the sclera, conjunctiva, and cornea. More particularly, the invention pertains to the application of therapeutic and other fluids for moisturizing and treating the surface of the eye.

## 10 BACKGROUND OF THE INVENTION

In normal situations, the surface of the eye, including the sclera, the conjunctiva, and the cornea, is kept moist by the presence of a tear film. This tear film is found in virtually all terrestrial vertebrates, with the exception of snakes.

The surface area of the eye in an adult human is about 2 cm<sup>2</sup>. It is covered by a complex tear film having a trilaminar structure, with each of the layers having a discrete and necessary function.

Nearest to the surface of the eye is an inner layer of mucus approximately 10 to 20  $\mu$ m in thickness. The mucus in this layer stabilizes the tear film and provides for attachment of the tear film to the underlying cornea and conjunctiva. The mucus also reduces the surface tension between the tear film and the eye and so permits the tear film to spread evenly across the eye.

The middle layer of the eye is an aqueous layer that is composed largely of water, electrolytes, and various proteins. This layer contains about 2 to 5  $\mu$ l of aqueous fluid and forms the bulk of the tear film. Within this layer, pH, osmotic pressure, oxygen tension, and the levels of electrolytes such as potassium, calcium, chloride, inorganic phosphates, and acids such as lactic acid and citric acid, are maintained within narrow physiologic ranges. Proteins present in the aqueous layer of the tear film include albumin, and other

proteins, such as immunoglobulins, interferon,  $\beta$ -lysin, and lysozyme which have antimicrobial activities.

Farthest from the surface of the eye is a lipid layer, which may range in thickness from a single  
5 monolayer to nearly 200 nm. Ordinarily, this layer is about 100 nm thick. This layer serves to retard evaporation of the tear film.

The tear film rapidly decreases in thickness following a blink. Without a subsequent blink, holes  
10 will begin to form in the tear film, called tear breakup, within about 30 seconds. Tear breakup times lower than 10 seconds are considered to be abnormal. This can occur with decreased tear formation or deficiencies in the mucus layer of the tear film. Other situations that can  
15 result in dryness of the eye surface include environmental aridity, contact lens wearing, and upon waking.

Typically, dryness of the eye is treated with water based solutions containing electrolytes and  
20 preservatives which maintain sterility of the solution for multiple applications. Solutions without preservatives are usually packaged in containers that provide for a single use, with disposal of the container and any residual solution following the single  
25 application.

The solutions are generally applied by drops, which provide about 20 to 25  $\mu$ l of fluid to the eye surface. The application of eye drops results in rapid moisturizing of the eye. However, because the amount  
30 delivered is greater than the volume of the tear film, these drops have the disadvantage of flooding the eye, which washes away the tear film and replaces the tear film with the fluid that comprises the drops. Immediately following this flooding there exists a period  
35 of time when the normal tear film, with its three layer structure and the constituents of each layer, is not present on the eye surface. This can result in

incomplete eye moisturizing which lasts for several blink cycles.

Other methods of administration of liquids onto the surface of the eye include eye cups, aerosol and pump sprays, and misters. Eye cups are used to bathe the surface of the eye in fluid, which results in flooding and washing away the tear film that is present on the eye surface. A mister that can be used to deliver a spray of droplets to the eye is described in Hahn, U.S. Patents Nos. 5,346,132 and 5,893,515, each of which is incorporated herein by reference. In these patents, Hahn discloses several disadvantages of delivering fluid to the eye by drops, including difficulty in positioning the dropper and incomplete delivery of medications due to missing the eye and spilling onto the face. Hahn does not address the issue of the quantity of fluid that is administered to the eye or the issue of washing away the tear film due to flooding. The mister of Hahn delivers a measurable quantity of fluid and can be used for household or medical purposes or to moisturize the eyes or the skin.

Another mister is described in Hutson, U.S. Patent No. 5,588,564, incorporated herein by reference. Like the mister of Hahn, the mister of Hutson can be used to deliver an adjustable and repeatable dose of fluid to the surface of the eye. Hutson does not address the issue of the quantity of fluid that is administered to the eye or the issue of washing away the tear film due to flooding.

A need exists for a method to moisturize the surface of the eye without flooding the eye or destroying the integrity of the natural tear film.

#### BRIEF SUMMARY OF THE INVENTION

It has been unexpectedly discovered that administering an amount of fluid to the surface of the eye at a level below that which results in flooding and

washing away the tear film results in an improvement in eye moisturizing over prior art methods.

In one embodiment, the invention is a method for moisturizing the eye. The method according to the invention includes obtaining an applicator that can controllably deliver an aqueous fluid to the surface of the eye in a quantity below that which will flood the eye. In this manner, the method of the invention serves to rehydrate the aqueous layer of the tear film and leaves the normal trilaminar tear film intact. In accordance with the method of the invention, the quantity of fluid that is administered to the eye surface is less than about two times the volume of the normal aqueous layer of the tear film, that is less than about 10  $\mu$ l. Preferably, between 0.5 and 6  $\mu$ l is administered, and most preferably, between 2 and 5  $\mu$ l is administered. The fluid may be administered to the eye surface in a single bolus, or may be administered over time, in ten seconds or less, preferably 5 seconds or less, in accordance with the invention.

The fluid may be delivered as drops, but is most preferably delivered as a fine mist. It has been discovered that aqueous fluids in the form of a fine mist are extremely well suited for rehydrating the aqueous portion of the tear film, without rinsing away the tear film.

In another embodiment, the invention is a kit for delivering a pharmaceutical composition for treating the eye, such as moisturizing the eye. In accordance with the invention, the kit contains an aqueous fluid pharmaceutical composition, a container that holds the pharmaceutical composition, and an applicator that, when actuated, controllably administers between about 0.5 and 50  $\mu$ l of the pharmaceutical composition to a surface of about 2 cm<sup>2</sup> in about 10 seconds or less, preferably about 5 seconds or less. Preferably, the kit further contains



instructions to controllably apply the pharmaceutical composition to the surface of the eye using the kit.

#### BRIEF DESCRIPTION OF THE DRAWING

5           FIG. 1 shows one embodiment of the kit of the invention for moisturizing the eye in accordance with the method of the invention.

#### DETAILED DESCRIPTION OF THE INVENTION

10           It has been discovered that a sudden increase in humidity to the tear film, as opposed to a splash of fluid such as occurs with presently available droppers and misters, increases the water content of the tear film while causing little or no displacement of the tear film.

15           In accordance with the invention, the volume of the tear film the surface of the eye is increased by applying a fluid in an amount not greater than about 100 to 200% of the volume of the aqueous portion of the tear film, which generally has a volume of 2 to 5  $\mu$ l. Thus,  
20           in accordance with the invention, about 10  $\mu$ l or less is applied to the surface of the eye. Preferably, 0.5 to 6  $\mu$ l is applied, and most preferably 1 to 2  $\mu$ l is applied, especially when moisturizing the eye because of the presence of dry eye, in which the total tear volume  
25           is typically between 1 to 2  $\mu$ l. The volume of fluid in accordance with the invention acts to rehydrate the aqueous portion of the tear film and maintains the integrity of the overlying lipid and the underlying mucus layers.

30           In contrast with the present state of the art in which 20 to 50  $\mu$ l of fluid is applied to the eye by dropper or by spray, the method in accordance with the invention reestablishes the normal state in individuals with dry eye. Present methods merely wash away the  
35           existing tear film and replace the tear film, or at least the middle aqueous layer, with an aqueous solution. These solutions lack the structure of the intact tear

05614750-071000

film and also differs from the normal aqueous layer of the tear film.

Generally, the above amount of fluid which is applied in accordance with the invention is applied during one blink cycle, that is between blinks. However, the fluid may be applied during a period of time in which one or more blinks occurs. Preferably, the fluid is applied within a period of 5 to 10 seconds or less.

Although the fluid may be administered in any form, including drops, dispersed droplets in air (mist), or a vapor, it is preferred that the fluid be administered in the form of a fine mist of discrete liquid droplets in which the average size of the fluid droplets is between about 5 and 150 microns in diameter. It has been found that a fine mist composed of droplets of this size range, preferably between about 0.1% to 1% of the tear volume per droplet, provides optimal hydration of the tear film and moisturization of the surface of the eye. Preferably, the average size of the fluid droplets is less than 100 microns, and more preferably less than 75 microns. Most preferably, the droplets have a diameter between 10 and 50 microns, with a most preferred range between 15 and 30 microns in diameter. Droplets above about 100 microns in diameter tend to incompletely vaporize and will fall out and produce undesirable wetting of the face and on horizontal surfaces. Droplets below about 20 microns in diameter are generally considered to be inhalable and can be aspirated into the upper and lower respiratory passages. This is acceptable when delivering a substance to the surface of the eye which is not potentially harmful to the respiratory system, such as a water. However, this may be undesirable when topical or ophthalmic medications are incorporated in the solution to be administered into the eye, when such medications may be irritating or toxic if inhaled.

5

10

15

20

25

35

medications to the surface of the eye, even though the medications cause irritation. Examples of suitable therapeutic medications that are suitable for use in the method of the invention include antibiotics, including  
5 antibacterial, antifungal, and antiviral agents, sympathetic and parasympathetic agents, anti-glaucoma agents, and anti-inflammatory agents such as steroids.

In another embodiment, the invention is a kit for administering a controlled dosage of between 0.5 and  
10 less than 20  $\mu\text{l}$  of an aqueous fluid to the surface of the eye. Preferably, the controlled dosage is less than 10  $\mu\text{l}$  and most preferably less than 5  $\mu\text{l}$ . In the most preferred embodiment, the controlled dosage is between 1 and 2  $\mu\text{l}$  of fluid. In accordance with the invention, the  
15 kit contains a container, an aqueous fluid within the container, and an actuator that delivers a spray or fine mist of fluid in the dosage described above. It is preferred that the mist be composed of discrete droplets having an average size of about 5 to 150 microns in  
20 diameter, most preferably less than 100 microns, even more preferably less than 75 microns, most preferably less between 10 and 50 microns with a most preferred range between 15 and 30 microns in diameter. The kit may further contain instructions to apply the controlled  
25 dosage of the aqueous fluid to the surface of the eye. Preferably, the container of the kit is hermetically sealed so that it may be used for multiple applications of the aqueous fluid over several days to months without the need to include a preservative in the fluid.

30 A preferred embodiment of the kit of the invention is shown diagrammatically in FIG. 1. FIG. 1 shows a package such as a box 101 for containing a rigid, preferably metallic, hermetically sealed container 102, inside of which is an inner hermetically sealed flexible  
35 pouch 103, which contains a fluid to be dispensed. There is a pressurization agent such as compressed air or nitrogen 104 between the hermetically sealed container

102 and the flexible pouch 103, and an actuator 105 that permits the proper dosage of the fluid in the pouch 103 to escape when depressed. The kit further contains instructions (not shown) for delivering a pre-determined dosage of the fluid into the eye.

The invention is further described in the following non-limiting examples.

#### Example 1

The volume of the tear film on the eyes of three adult human subjects is measured and determined to average  $2.26 \mu\text{l}$ . The subjects are then treated by administering to surface of their eyes fine mist of between 50 and 100 micron average droplet size, with a total volume of between 2 to  $5 \mu\text{l}$  within a period of 10 seconds per eye. Following administration, the tear volume is again measured and is determined to average  $2.96 \mu\text{l}$ .

#### Example 2

Samples of the tear film from three adult human subjects are obtained and subjected to HPLC chromatography to determine the baseline level of proteins and other constituents in the tear film. One eye from each of the subjects is then moisturized by administration of a standard drop of artificial tears of between 25 and  $50 \mu\text{l}$ . Samples of the tear film from the three treated eyes are then obtained and subjected to HPLC chromatography. After obtaining the second group of samples, the opposite eye of each of the subjects is then moisturized by administration of the same artificial tears but in a fine mist made of droplets having a size between 50 and 100 microns for a total volume of about  $5 \mu\text{l}$ . Samples of the tear film from the mist-treated eyes are then obtained and subjected to HPLC chromatography. The artificial tears are also subjected to HPLC chromatography.

The initial HPLC chromatography provides a profile of the constituents found in the normal tear film. It is found to contain various lipids, mucus, proteins, and electrolytes.

5           The HPLC chromatography following moisturization by a single large drop reveals that most if not all of the lipids and mucus remain in the tear film. The proteins and electrolytes that are present in the normal tear film are no longer present and the tear  
10 film has a chromatography profile similar to that of the artificial tears, minus the lipids and mucus.

          The HPLC chromatography following moisturization by the fine mist reveals that the lipids and mucus remain in the tear film. The proteins and  
15 electrolytes that are present in the normal tear film are demonstrated by the chromatography to remain in the tear film following moisturization by the fine mist.

          Further modifications, uses, and applications of the invention described herein will be apparent to  
20 those skilled in the art. It is intended that such modifications be encompassed in the following claims.

## CLAIMS

1. A method for moisturizing the eye comprising controllably administering to the surface of the eye an aqueous fluid in an amount that is sufficient to increase the volume of the aqueous layer of the tear film by at least 5% of the volume of the normal aqueous layer and which amount is less than that which causes runoff of the tear film from the eye and permitting the fluid to hydrate the aqueous layer of the tear film.

2. The method of claim 1 wherein the amount of fluid is between 50 and 200% of the volume of the normal aqueous layer of the tear film.

3. The method of claim 1 wherein the fluid is administered in the form of a mist.

4. The method of claim 3 wherein the mist is composed of droplets having an average volume of about 0.1% to 1% of the volume of the normal tear film.

5. The method of claim 3 wherein the mist is composed of droplets having an average size of between about 5 and 150 microns in diameter.

6. The method of claim 5 wherein the average size of the droplets is between 10 and 50 microns in diameter.

7. The method of claim 6 wherein the average size of the droplets is between 15 and 30 microns in diameter.

8. The method of claim 1 wherein quantity of fluid that is administered to the eye surface is less than about 10  $\mu$ l.

9. The method of claim 8 wherein the quantity is between about 0.5 and 6  $\mu$ l.

10. The method of claim 9 wherein the quantity  
5 is between about 2 and 5  $\mu$ l.

11. The method of claim 1 wherein the fluid has administered has an osmolarity of less than that of the normal aqueous layer of the tear film.

10

12. The method of claim 11 wherein the osmolarity is less than 311 mOsm.

13. The method of claim 1 wherein the pH of  
15 the fluid is less than 7.

14. The method of claim 13 wherein the pH is about 6.5.

15. A method for moisturizing the surface of the eye comprising administering to said surface of the eye between 0.5 and 20  $\mu$ l of an aqueous fluid within about 10 seconds and permitting said fluid to hydrate the aqueous layer of the tear film of said eye.

25

16. The method of claim 15 wherein the administration is by a mist having an average droplet size between 5 and 150 microns in diameter.

17. The method of claim 16 wherein the droplet size is between 10 and 50 microns in diameter.

30

18. The method of claim 17 wherein the droplet size is between 15 and 30 microns in diameter.



19. A kit for moisturizing the eye comprising a container, a fluid within said container, an actuator that delivers between 0.5 and 20  $\mu$ l of said fluid within about 10 seconds, and instructions for delivering said  
5 dose of fluid to the surface of the eye.

20. The kit of claim 19 wherein the actuator delivers the fluid as a mist having an average droplet size between 50 and 150 microns in diameter.  
10

21. The kit of claim 20 wherein the average droplet size is between 10 and 50 microns in diameter.

22. The kit of claim 21 wherein the average  
15 droplet size is between about 15 and 30 microns in diameter.

23. A method for moisturizing the eye comprising administering to the surface of said eye  
20 between 0.5 and 10  $\mu$ l of an aqueous fluid wherein said fluid is in the form of a mist comprised of droplets having an average size between 5 and 150 microns and wherein the fluid has a pH less than or equal to 7.0 and an osmolarity below that of the normal tear film and  
25 permitting said fluid to rehydrate the aqueous portion of the tear film of said eye.

## METHOD AND KIT FOR MOISTURIZING THE SURFACE OF THE EYE

## ABSTRACT OF THE INVENTION

5 A method for moisturizing the eye in which an  
amount of aqueous fluid is administered to the eye in an  
amount below that which causes flooding of the eye and  
removal of the normal tear film from the surface of the  
eye. The fluid, when administered in accordance with the  
invention, rehydrates the already present tear film  
10 rather than replacing the tear film. A kit for  
moisturizing the eye in accordance with the invention is  
also disclosed.

15

20

25

30




FIGURE 1

## DECLARATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHOD AND KIT FOR MOISTURIZING THE SURFACE OF THE EYE

the specification of which

☒ is attached hereto.

☐ was filed on \_\_\_\_\_ as  
Application Serial No. \_\_\_\_\_  
and was amended on \_\_\_\_\_  
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority  
Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

(Application Serial No.)	(Filing Date)
1	1/1/1970
2	1/1/1970
3	1/1/1970
4	1/1/1970
5	1/1/1970
6	1/1/1970
7	1/1/1970
8	1/1/1970
9	1/1/1970
10	1/1/1970
11	1/1/1970
12	1/1/1970
13	1/1/1970
14	1/1/1970
15	1/1/1970
16	1/1/1970
17	1/1/1970
18	1/1/1970
19	1/1/1970
20	1/1/1970
21	1/1/1970
22	1/1/1970
23	1/1/1970
24	1/1/1970
25	1/1/1970
26	1/1/1970
27	1/1/1970
28	1/1/1970
29	1/1/1970
30	1/1/1970
31	1/1/1970
32	1/1/1970
33	1/1/1970
34	1/1/1970
35	1/1/1970
36	1/1/1970
37	1/1/1970
38	1/1/1970
39	1/1/1970
40	1/1/1970
41	1/1/1970
42	1/1/1970
43	1/1/1970
44	1/1/1970
45	1/1/1970
46	1/1/1970
47	1/1/1970
48	1/1/1970
49	1/1/1970
50	1/1/1970
51	1/1/1970
52	1/1/1970
53	1/1/1970
54	1/1/1970
55	1/1/1970
56	1/1/1970
57	1/1/1970
58	1/1/1970
59	1/1/1970
60	1/1/1970
61	1/1/1970
62	1/1/1970
63	1/1/1970
64	1/1/1970
65	1/1/1970
66	1/1/1970
67	1/1/1970
68	1/1/1970
69	1/1/1970
70	1/1/1970
71	1/1/1970
72	1/1/1970
73	1/1/1970
74	1/1/1970
75	1/1/1970
76	1/1/1970
77	1/1/1970
78	1/1/1970
79	1/1/1970
80	1/1/1970
81	1/1/1970
82	1/1/1970
83	1/1/1970
84	1/1/1970
85	1/1/1970
86	1/1/1970
87	1/1/1970
88	1/1/1970
89	1/1/1970
90	1/1/1970
91	1/1/1970
92	1/1/1970
93	1/1/1970
94	1/1/1970
95	1/1/1970
96	1/1/1970
97	1/1/1970
98	1/1/1970
99	1/1/1970
100	1/1/1970

(Application Serial No.)	(Filing Date)
1	1/1/1980
2	1/1/1980
3	1/1/1980
4	1/1/1980
5	1/1/1980
6	1/1/1980
7	1/1/1980
8	1/1/1980
9	1/1/1980
10	1/1/1980
11	1/1/1980
12	1/1/1980
13	1/1/1980
14	1/1/1980
15	1/1/1980
16	1/1/1980
17	1/1/1980
18	1/1/1980
19	1/1/1980
20	1/1/1980
21	1/1/1980
22	1/1/1980
23	1/1/1980
24	1/1/1980
25	1/1/1980
26	1/1/1980
27	1/1/1980
28	1/1/1980
29	1/1/1980
30	1/1/1980
31	1/1/1980
32	1/1/1980
33	1/1/1980
34	1/1/1980
35	1/1/1980
36	1/1/1980
37	1/1/1980
38	1/1/1980
39	1/1/1980
40	1/1/1980
41	1/1/1980
42	1/1/1980
43	1/1/1980
44	1/1/1980
45	1/1/1980
46	1/1/1980
47	1/1/1980
48	1/1/1980
49	1/1/1980
50	1/1/1980
51	1/1/1980
52	1/1/1980
53	1/1/1980
54	1/1/1980
55	1/1/1980
56	1/1/1980
57	1/1/1980
58	1/1/1980
59	1/1/1980
60	1/1/1980
61	1/1/1980
62	1/1/1980
63	1/1/1980
64	1/1/1980
65	1/1/1980
66	1/1/1980
67	1/1/1980
68	1/1/1980
69	1/1/1980
70	1/1/1980
71	1/1/1980
72	1/1/1980
73	1/1/1980
74	1/1/1980
75	1/1/1980
76	1/1/1980
77	1/1/1980
78	1/1/1980
79	1/1/1980
80	1/1/1980
81	1/1/1980
82	1/1/1980
83	1/1/1980
84	1/1/1980
85	1/1/1980
86	1/1/1980
87	1/1/1980
88	1/1/1980
89	1/1/1980
90	1/1/1980
91	1/1/1980
92	1/1/1980
93	1/1/1980
94	1/1/1980
95	1/1/1980
96	1/1/1980
97	1/1/1980
98	1/1/1980
99	1/1/1980
100	1/1/1980

I hereby claim the benefit under Title 35, United States Code, §120, of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Ser. No.)	(Filing Date)	(Status) (patented, pending, abandoned)
------------------------	---------------	---

(Application Ser. No.)	(Filing Date)	(Status) (patented, pending, abandoned)
100-100000	10/1/1950	patented
100-100001	10/1/1950	pending
100-100002	10/1/1950	abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature:

**Dated:**

Full name of first joint inventor

Residence

## Citizenship

Post Office Address

Sharon F. Klevne

Grants Pass, Oregon

U.S.A.

5001 Lower River Road

Grants Pass, OR 97526

Atty Docket No. 7982.001/hme

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## PATENT APPLICATION

## PATENT EXAMINING OPERATIONS

Applicant : Sharon F. Kleyne      Group Art Unit:  
Serial No.: Not yet known      Examiner:  
Filed : Herewith  
Title : METHOD AND KIT FOR  
         MOISTURIZING THE SURFACE  
         OF THE EYE

## POWER OF ATTORNEY

I, Sharon F. Kleyne, declare that I am the sole inventor the above-identified patent application and hereby appoint Howard M. Eisenberg, Reg. No. 36,789, Jacob E. Vilhauer, Jr., Reg. No. 24,885, Charles D. McClung, Reg. No. 26,568, Dennis E. Stenzel, Reg. No. 28,763, Donald B. Haslett, Reg. No. 28,855, J. Peter Staples, Reg. No. 30,690, William O. Geny, Reg. No. 27,444, Nancy J. Moriarty, Reg. No. 40,733, Bruce W. DeKock, Reg. No. 40,585, Kevin L. Russell, Reg. No. 38,292, and Timothy A. Long, Reg. No. 28,876, all members of the firm of CHERNOFF, VILHAUER, McCLUNG & STENZEL, LLP, 1600 ODS Tower, 601 S.W. Second Avenue, Portland, Oregon 97204-3157, telephone No. (503) 227-5631, its attorneys, jointly and individually, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated: July 10, 2000

  
Sharon F. Kleyne